icrn/ens-cca translational science webinar series: "role of cytotoxic chemo in cholangiocarcinoma”
Published 3 years ago • 443 plays • Length 59:37Download video MP4
Download video MP3
Similar videos
-
57:28
icrn/ens-cca translational science webinar series: "next steps with fgfri”
-
42:08
icrn/ens-cca webinar: "psc & cholangiocarcinoma – where the research stands on the interconnection"
-
53:54
icrn/ens-cca webinar: "advantages & disadvantages of various animal models in cholangiocarcinoma”
-
59:21
icrn webinar: supermassive intrahepatic cca: clinicogenomic analysis & role of ablative radiotherapy
-
25:31
icrn webinar: genomic & epigenomic landscape of cholangiocarcinoma
-
1:08:19
boost your immune system using ppars by mr shyan, simplyhealed webinar
-
57:04
regulation of cns inflammation by astrocytes by dr. francisco quintana
-
1:00:37
update on perihilar cholangiocarcinoma: diagnosis, management, and endoscopic ablation therapy
-
59:14
icrn webinar: the role and impact of psc in bile duct disease and cca
-
59:00
icrn webinar: immune landscape of cholangiocarcinoma
-
1:02:13
icrn webinar: "innovative surgical approaches to cholangiocarcinoma – transplant and beyond”
-
1:04:29
icrn/ens-cca webinar: "challenges of designing immune trials in the second line with review of data"
-
56:28
webinar: “the perio-02 trial – enabling immunotherapy for intrahepatic cholangiocarcinoma”
-
38:40
icrn: ablative radiation for intrahepatic cholangiocarcinoma: current status & future directions
-
1:07:40
icrn webinar: btc - epidemiology, molecular characteristics, and the power of intl collaborations
-
40:50
icrn webinar: drug repurposing in cholangiocarcinoma – identifying leads from the literature
-
51:48
webinar: novel treatment approaches for intrahepatic cholangiocarcinoma
-
58:22
icrn webinar: arid1a and cca
-
1:04:34
icrn webinar: morphomolecular characterization of early and progressed cholangiocarcinoma
-
56:36
icrn webinar: targeting immunosuppressive myeloid cells in cholangiocarcinoma
-
56:26
webinar: is immunotherapy a good treatment option for all patients with cholangiocarcinoma?